Onkologie. 2010:4(3):177-180

The treatment of recurrent cervical cancer

Josef Chovanec1, Zuzana Dostálová2, Petr Novák1, Helena Kolářová1
1 Oddělení gynekologické onkologie, MOU Brno
2 Gynekologicko porodnická klinika Fakultní nemocnice Brno

The recurrence rate of cervical cancer is between 10–20 % for FIGO stages IB–IIA and 50–70 % for FIGO stages IIB–IVA. When cervical

cancer is beyond curative treatment by surgery or radiotherapy, the prognosis is poor. The patiens with recurrent cervical cancer have

1 year – survival rate between 15–20 %. Palliation therapy is the primary objective. Recurrent lesions not amenable to radical local exscision

or regional radiation are treated with paliative chemotherapy. Low response and short overall survival are disappointing. The need

for novel agents and further research focused on the management of recurrent cervical cancer remains. For future trials it is necessary

to incorporate biological agents to chemotherapy.

Keywords: recurrence, cervical cancer, therapy

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chovanec J, Dostálová Z, Novák P, Kolářová H. The treatment of recurrent cervical cancer. Onkologie. 2010;4(3):177-180.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ÚZIS ČR, NOR ČR, 2010: 69,71.
    2. Moore DH. Chemotherapy for advanced, recurrent and metastatic cervical cancer. J. Nat. Compreh. Cancer Network, 2008; 8(1): 53-57. Go to original source... Go to PubMed...
    3. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. Int. J. Gynaecol. Obstet., 2003; 83(Suppl.1): 41-78. Go to original source... Go to PubMed...
    4. Cibula D, Petruželka L a kolektiv. Onkogynekologie, 1. vydání, Grada Publishing a.s., Praha, 2009: 444-445.
    5. Hoskins WJ, Perez CA, Young RC. Principles and practise of Gynecologic Oncology, 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2005: 771.
    6. Chen HS, Sheen-Chen SM. Total pelvic exenteration for primary local advanced colorectal cancer. World J. Surg. 2001; 25: 1546-1549. Go to original source... Go to PubMed...
    7. Ferenschild FTC, Vermaas M, Verhoef C, et al. Total pelvic exenteration for primary and recurrent malignancies. World J. Surg., 2009; 33: 1502-1508. Go to original source... Go to PubMed...
    8. Cibula D, Petruželka L a kolektiv. Onkogynekologie, 1. vydání, Grada Publishing a.s., Praha, 2009: 449.
    9. Šlampa P a kolektiv. Radiační onkologie v praxi, 2. vydání, Masarykův onkologický ústav, Brno, 2007: 125.
    10. Pectasides D, Kamposioras G, Papaxoinis G. Chemotherapy for recurrent cervical cancer. Canc. Treatm. Reviews, 2008; 34: 603-613. Go to original source... Go to PubMed...
    11. Thigpen JT, Vance R, Puneky L, et al. Chemotherapy as a palliative treatment in carcinoma of the uterine cervix: Semin Oncol 1995; 22(Suppl. 3): 16-24.
    12. Omura GA, Biessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix. a Gynecologic Oncology Group study. J. Clin. Oncol. 1997; 15(1): 165-171. Go to original source... Go to PubMed...
    13. Blosss JD, Blessing JA, Behrens B, et al. Randomized trial of cisplatin and ifosfamid with or without bleomycin in squamous carcinoma of the cervix. A Gynecologic Oncology Group study. J. Clin. Oncol. 2002; 20: 1832-1837. Go to original source... Go to PubMed...
    14. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 2004; 22: 3113-3119. Go to original source... Go to PubMed...
    15. Fiorica J, Holloway R, Ndubisi B, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol. Oncol. 2002; 85: 89-94. Go to original source... Go to PubMed...
    16. Long III HJ, Gross WG, Wieand HS, et al. Phase II trial of methotrexate, vinblastine, doxorubicin and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol. Oncol. 1995; 57: 235-239. Go to original source... Go to PubMed...
    17. Long III HJ, Bundy BN, Grendys Jr EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study, J. Clin. Oncol. 2005; 23: 4629-4633. Go to original source... Go to PubMed...
    18. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 2009; 27(28): 4649-4655. Go to original source... Go to PubMed...
    19. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2009; 27(7): 1069-1074. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.